{"check":null,"uid":"a63f871817554dde","title":"H.R. 10887 (IH) - Protecting Consumer Access to Generic Drugs Act of 2026","title_generated":false,"country":"США","organ":"Конгресс США","kind":"law","kind_name":"Законодательство","lang":"en","date":"2026-10-23","summary":"Закон запрещает брендам компенсировать производителям генерических лекарств за задержку выхода их продукции на рынок. Устанавливает правила заключения соглашений между держателями регистрационных удостоверений и последующими заявителями, ограничивая компенсации и условия таких соглашений. Предусматривает ответственность Федеральной торговой комиссии за соблюдение этих правил и устанавливает срок давности для подачи исков.","snippet":"","topics":["Цифровые платформы и сервисы"],"status":"ok","error":"","text_len":20277,"versions":1,"url":"https://www.congress.gov/bill/119th-congress/house-bill/10887","first_seen":"2026-10-29","last_checked":"2026-11-16 05:18","relevance":"hit","score":3,"query":"","source_key":"congress_us","verdict":{"relevance":"hit","score":3,"topics":["Цифровые платформы и сервисы"],"need_body":3,"authorities":[{"kind":"орган","name":"Federal Trade Commission","topic":"Цифровые платформы и сервисы"}],"evidence":[{"topic":"Цифровые платформы и сервисы","term":"Federal Trade Commission","weak":false,"pos":3725,"ctx":"not to sue on any claim that such covered product infringes a patent. (d) Enforcement by Federal Trade Commission.-- (1) General application.--The requirements of this section apply, according to their t","zone":"орган","weight":3}],"dropped":[{"topic":"Конкуренция на цифровых рынках","term":"antitrust","weak":true,"pos":10964,"ctx":"reements to be in furtherance of market competition and for the benefit of consumers. (f) antitrust laws.--nothing in this section shall modify, impair, limit, or supersede the applicabilit","why":"только многозначные термины"},{"topic":"Конкуренция на цифровых рынках","term":"antitrust","weak":true,"pos":11072,"ctx":"othing in this section shall modify, impair, limit, or supersede the applicability of the antitrust laws as defined in subsection (a) of the first section of the clayton act (15 u.s.c. 12(a","why":"только многозначные термины"},{"topic":"Конкуренция на цифровых рынках","term":"antitrust","weak":true,"pos":11481,"ctx":"ght of a subsequent filer to assert claims or counterclaims against any person, under the antitrust laws or other laws relating to unfair competition. (g) definitions.--in this section: (1)","why":"только многозначные термины"}]},"last_changed":"2026-10-29","meta":{"govinfo_package":"BILLS-119hr10887ih","type":"HR","textVersion":"ih","via":"govinfo_rss","date_kind":"publication","coverage":"latest_100_publications"},"source_url":"https://www.congress.gov/bill/119th-congress/house-bill/10887","text":"[Congressional Bills 119th Congress]\n[From the U.S. Government Publishing Office]\n[H.R. 10887 Introduced in House (IH)]\n\n<DOC>\n\n119th CONGRESS\n2d Session\nH. R. 10887\n\nTo prohibit brand name drug manufacturers from compensating generic\ndrug manufacturers to delay the entry of a generic drug into the\nmarket, to prohibit biological product manufacturers from compensating\nbiosimilar and interchangeable product manufacturers to delay entry of\nbiosimilar and interchangeable products, and for other purposes.\n\n_______________________________________________________________________\n\nIN THE HOUSE OF REPRESENTATIVES\n\nOctober 22, 2026\n\nMr. Magaziner introduced the following bill; which was referred to the\nCommittee on Energy and Commerce, and in addition to the Committee on\nthe Judiciary, for a period to be subsequently determined by the\nSpeaker, in each case for consideration of such provisions as fall\nwithin the jurisdiction of the committee concerned\n\n_______________________________________________________________________\n\nA BILL\n\nTo prohibit brand name drug manufacturers from compensating generic\ndrug manufacturers to delay the entry of a generic drug into the\nmarket, to prohibit biological product manufacturers from compensating\nbiosimilar and interchangeable product manufacturers to delay entry of\nbiosimilar and interchangeable products, and for other purposes.\n\nBe it enacted by the Senate and House of Representatives of the\nUnited States of America in Congress assembled,\n\nSECTION 1. SHORT TITLE.\n\nThis Act may be cited as the ``Protecting Consumer Access to\nGeneric Drugs Act of 2026''.\n\nSEC. 2. UNLAWFUL AGREEMENTS.\n\n(a) Agreements Prohibited.--Subject to subsections (b) and (c), it\nshall be unlawful for an NDA or BLA holder and a subsequent filer (or\nfor two subsequent filers) to enter into, or carry out, an agreement\nresolving or settling a covered patent infringement claim on a final or\ninterim basis if under such agreement--\n(1) a subsequent filer directly or indirectly receives from\nsuch holder (or in the case of such an agreement between two\nsubsequent filers, the other subsequent filer) anything of\nvalue, including a license; and\n(2) the subsequent filer agrees to limit or forego research\non, or development, manufacturing, marketing, or sales of, for\nany period of time, the covered product that is the subject of\nthe application described in subparagraph (A) or (B) of\nsubsection (g)(8).\n(b) Exclusion.--It shall not be unlawful under subsection (a) if a\nparty to an agreement described in such subsection demonstrates by\nclear and convincing evidence that the value described in subsection\n(a)(1) is compensation solely for other goods or services that the\nsubsequent filer has promised to provide.\n(c) Limitation.--Nothing in this section shall prohibit an\nagreement resolving or settling a covered patent infringement claim in\nwhich the consideration granted by the NDA or BLA holder to the\nsubsequent filer (or from one subsequent filer to another) as part of\nthe resolution or settlement includes only one or more of the\nfollowing:\n(1) The right to market the covered product that is the\nsubject of the application described in subparagraph (A) or (B)\nof subsection (g)(8) in the United States before the expiration\nof--\n(A) any patent that is the basis of the covered\npatent infringement claim; or\n(B) any patent right or other statutory exclusivity\nthat would prevent the marketing of such covered\nproduct.\n(2) A payment for reasonable litigation expenses not to\nexceed $7,500,000 in the aggregate.\n(3) A covenant not to sue on any claim that such covered\nproduct infringes a patent.\n(d) Enforcement by Federal Trade Commission.--\n(1) General application.--The requirements of this section\napply, according to their terms, to an NDA or BLA holder or\nsubsequent filer that is--\n(A) a person, partnership, or corporation over\nwhich the Commission has authority pursuant to section\n5(a)(2) of the Federal Trade Commission Act (15 U.S.C.\n45(a)(2)); or\n(B) a person, partnership, or corporation over\nwhich the Commission would have authority pursuant to\nsuch section but for the fact that such person,\npartnership, or corporation is not organized to carry\non business for its own profit or that of its members.\n(2) Unfair or deceptive acts or practices enforcement\nauthority.--\n(A) In general.--A violation of this section shall\nbe treated as an unfair or deceptive act or practice in\nviolation of section 5(a)(1) of the Federal Trade\nCommission Act (15 U.S.C. 45(a)(1)).\n(B) Powers of commission.--Except as provided in\nsubparagraph (C) and paragraphs (1)(B) and (3)--\n(i) the Commission shall enforce this\nsection in the same manner, by the same means,\nand with the same jurisdiction, powers, and\nduties as though all applicable terms and\nprovisions of the Federal Trade Commission Act\n(15 U.S.C. 41 et seq.) were incorporated into\nand made a part of this section; and\n(ii) any NDA or BLA holder or subsequent\nfiler that violates this section shall be\nsubject to the penalties and entitled to the\nprivileges and immunities provided in the\nFederal Trade Commission Act.\n(C) Judicial review.--In the case of a cease and\ndesist order issued by the Commission under section 5\nof the Federal Trade Commission Act (15 U.S.C. 45) for\nviolation of this section, a party to such order may\nobtain judicial review of such order as provided in\nsuch section 5, except that--\n(i) such review may only be obtained in--\n(I) the United States Court of\nAppeals for the District of Columbia\nCircuit;\n(II) the United States Court of\nAppeals for the circuit in which the\nultimate parent entity, as defined in\nsection 801.1(a)(3) of title 16, Code\nof Federal Regulations, or any\nsuccessor thereto, of the NDA or BLA\nholder (if any such holder is a party\nto such order) is incorporated as of\nthe date that the application described\nin subparagraph (A) or (B) of\nsubsection (g)(8) or an approved\napplication that is deemed to be a\nlicense for a biological product under\nsection 351(k) of the Public Health\nService Act (42 U.S.C. 262(k)) pursuant\nto section 7002(e)(4) of the Biologics\nPrice Competition and Innovation Act of\n2009 (Public Law 111-148; 124 Stat.\n817) is submitted to the Commissioner\nof Food and Drugs; or\n(III) the United States Court of\nAppeals for the circuit in which the\nultimate parent entity, as so defined,\nof any subsequent filer that is a party\nto such order is incorporated as of the\ndate that the application described in\nsubparagraph (A) or (B) of subsection\n(g)(8) is submitted to the Commissioner\nof Food and Drugs; and\n(ii) the petition for review shall be filed\nin the court not later than 30 days after such\norder is served on the party seeking review.\n(3) Additional enforcement authority.--\n(A) Civil penalty.--The Commission may commence a\ncivil action to recover a civil penalty in a district\ncourt of the United States against any NDA or BLA\nholder or subsequent filer that violates this section.\n(B) Special rule for recovery of penalty if cease\nand desist order issued.--\n(i) In general.--If the Commission has\nissued a cease and desist order in a proceeding\nunder section 5 of the Federal Trade Commission\nAct (15 U.S.C. 45) for violation of this\nsection--\n(I) the Commission may commence a\ncivil action under subparagraph (A) to\nrecover a civil penalty against any\nparty to such order at any time before\nthe expiration of the 1-year period\nbeginning on the date on which such\norder becomes final under section 5(g)\nof such Act (15 U.S.C. 45(g)); and\n(II) in such civil action, the\nfindings of the Commission as to the\nmaterial facts in such proceeding shall\nbe conclusive, unless--\n(aa) the terms of such\norder expressly provide that\nthe Commission's findings shall\nnot be conclusive; or\n(bb) such order became\nfinal by reason of section\n5(g)(1) of such Act (15 U.S.C.\n45(g)(1)), in which case such\nfindings shall be conclusive if\nsupported by evidence.\n(ii) Relationship to penalty for violation\nof an order.--The penalty provided in clause\n(i) for violation of this section is separate\nfrom and in addition to any penalty that may be\nincurred for violation of an order of the\nCommission under section 5(l) of the Federal\nTrade Commission Act (15 U.S.C. 45(l)).\n(C) Amount of penalty.--\n(i) In general.--The amount of a civil\npenalty imposed in a civil action under\nsubparagraph (A) on a party to an agreement\ndescribed in subsection (a) shall be sufficient\nto deter violations of this section, but in no\nevent greater than--\n(I) if such party is the NDA or BLA\nholder (or, in the case of an agreement\nbetween two subsequent filers, the\nsubsequent filer who gave the value\ndescribed in subsection (a)(1)), the\ngreater of--\n(aa) 3 times the value\nreceived by such NDA or BLA\nholder (or by such subsequent\nfiler) that is reasonably\nattributable to the violation\nof this section; or\n(bb) 3 times the value\ngiven to the subsequent filer\n(or to the other subsequent\nfiler) reasonably attributable\nto the violation of this\nsection; and\n(II) if such party is the\nsubsequent filer (or, in the case of an\nagreement between two subsequent\nfilers, the subsequent filer who\nreceived the value described in\nsubsection (a)(1)), 3 times the value\nreceived by such subsequent filer that\nis reasonably attributable to the\nviolation of this section.\n(ii) Factors for consideration.--In\ndetermining such amount, the court shall take\ninto account--\n(I) the nature, circumstances,\nextent, and gravity of the violation;\n(II) with respect to the violator,\nthe degree of culpability, any history\nof violations, the ability to pay, any\neffect on the ability to continue doing\nbusiness, profits earned by the NDA or\nBLA holder (or, in the case of an\nagreement between two subsequent\nfilers, the subsequent filer who gave\nthe value described in subsection\n(a)(1)), compensation received by the\nsubsequent filer (or, in the case of an\nagreement between two subsequent\nfilers, the subsequent filer who\nreceived the value described in\nsubsection (a)(1)), and the amount of\ncommerce affected; and\n(III) other matters that justice\nrequires.\n(D) Injunctions and other equitable relief.--In a\ncivil action under subparagraph (A), the United States\ndistrict courts are empowered to grant mandatory\ninjunctions and such other and further equitable relief\nas they deem appropriate.\n(4) Remedies in addition.--Remedies provided in this\nsubsection are in addition to, and not in lieu of, any other\nremedy provided by Federal law.\n(5) Preservation of authority of commission.--Nothing in\nthis section shall be construed to affect any authority of the\nCommission under any other provision of law.\n(e) Federal Trade Commission Rulemaking.--The Commission may, in\nits discretion, by rule promulgated under section 553 of title 5,\nUnited States Code, exempt from this section certain agreements\ndescribed in subsection (a) if the Commission finds such agreements to\nbe in furtherance of market competition and for the benefit of\nconsumers.\n(f) Antitrust Laws.--Nothing in this section shall modify, impair,\nlimit, or supersede the applicability of the antitrust laws as defined\nin subsection (a) of the first section of the Clayton Act (15 U.S.C.\n12(a)), and of section 5 of the Federal Trade Commission Act (15 U.S.C.\n45) to the extent that such section 5 applies to unfair methods of\ncompetition. Nothing in this section shall modify, impair, limit, or\nsupersede the right of a subsequent filer to assert claims or\ncounterclaims against any person, under the antitrust laws or other\nlaws relating to unfair competition.\n(g) Definitions.--In this section:\n(1) Agreement resolving or settling a covered patent\ninfringement claim.--The term ``agreement resolving or settling\na covered patent infringement claim'' means any agreement\nthat--\n(A) resolves or settles a covered patent\ninfringement claim; or\n(B) is contingent upon, provides for a contingent\ncondition for, or is otherwise related to the\nresolution or settlement of a covered patent\ninfringement claim.\n(2) Commission.--The term ``Commission'' means the Federal\nTrade Commission.\n(3) Covered patent infringement claim.--The term ``covered\npatent infringement claim'' means an allegation made by the NDA\nor BLA holder to a subsequent filer (or, in the case of an\nagreement between two subsequent filers, by one subsequent\nfiler to another), whether or not included in a complaint filed\nwith a court of law, that--\n(A) the submission of the application described in\nsubparagraph (A) or (B) of paragraph (8), or the\nmanufacture, use, offering for sale, sale, or\nimportation into the United States of a covered product\nthat is the subject of such an application--\n(i) in the case of an agreement between an\nNDA or BLA holder and a subsequent filer,\ninfringes any patent owned by, or exclusively\nlicensed to, the NDA or BLA holder of the\ncovered product; or\n(ii) in the case of an agreement between\ntwo subsequent filers, infringes any patent\nowned by the subsequent filer; or\n(B) in the case of an agreement between an NDA or\nBLA holder and a subsequent filer, the covered product\nto be manufactured under such application uses a\ncovered product as claimed in a published patent\napplication.\n(4) Covered product.--The term ``covered product'' means a\ndrug (as defined in section 201(g) of the Federal Food, Drug,\nand Cosmetic Act (21 U.S.C. 321(g))), including a biological\nproduct (as defined in section 351(i) of the Public Health\nService Act (42 U.S.C. 262(i))).\n(5) NDA or bla holder.--The term ``NDA or BLA holder''\nmeans--\n(A) the holder of--\n(i) an approved new drug application filed\nunder section 505(b)(1) of the Federal Food,\nDrug, and Cosmetic Act (21 U.S.C. 355(b)(1))\nfor a covered product; or\n(ii) a biologics license application filed\nunder section 351(a) of the Public Health\nService Act (42 U.S.C. 262(a)) for a covered\nproduct;\n(B) a person owning or controlling enforcement of\nthe patent on--\n(i) the list published under section\n505(j)(7) of the Federal Food, Drug, and\nCosmetic Act (21 U.S.C. 355(j)(7)) in\nconnection with the application described in\nsubparagraph (A)(i); or\n(ii) any list published under section 351\nof the Public Health Service Act (42 U.S.C.\n262) comprised of patents associated with\nbiologics license applications filed under\nsection 351(a) of such Act (42 U.S.C. 262(a));\nor\n(C) the predecessors, subsidiaries, divisions,\ngroups, and affiliates controlled by, controlling, or\nunder common control with any entity described in\nsubparagraph (A) or (B) (such control to be presumed by\ndirect or indirect share ownership of 50 percent or\ngreater), as well as the licensees, licensors,\nsuccessors, and assigns of each of the entities.\n(6) Patent.--The term ``patent'' means a patent issued by\nthe United States Patent and Trademark Office.\n(7) Statutory exclusivity.--The term ``statutory\nexclusivity'' means those prohibitions on the submission or\napproval of drug applications under clauses (ii) through (iv)\nof section 505(c)(3)(E) (5- and 3-year exclusivity), clauses\n(ii) through (iv) of section 505(j)(5)(F) (5-year and 3-year\nexclusivity), section 505(j)(5)(B)(iv) (180-day exclusivity),\nsection 527 (orphan drug exclusivity), section 505A (pediatric\nexclusivity), or section 505E (qualified infectious disease\nproduct exclusivity) of the Federal Food, Drug, and Cosmetic\nAct (21 U.S.C. 355(c)(3)(E), 355(j)(5)(F), 355(j)(5)(B)(iv),\n360cc, 355a, 355f), or prohibitions on the submission or\nlicensing of biologics license applications under section\n351(k)(6) (interchangeable biological product exclusivity) or\nsection 351(k)(7) (biological product reference product\nexclusivity) of the Public Health Service Act (42 U.S.C.\n262(k)(6), (7)).\n(8) Subsequent filer.--The term ``subsequent filer''\nmeans--\n(A) in the case of a drug, a party that owns or\ncontrols an abbreviated new drug application submitted\npursuant to section 505(j) of the Federal Food, Drug,\nand Cosmetic Act (21 U.S.C. 355(j)) or a new drug\napplication submitted pursuant to section 505(b)(2) of\nthe Federal Food, Drug, and Cosmetic Act (21 U.S.C.\n355(b)(2)) and filed under section 505(b)(1) of such\nAct (21 U.S.C. 355(b)(1)) or has the exclusive rights\nto distribute the covered product that is the subject\nof such application; or\n(B) in the case of a biological product, a party\nthat owns or controls an application filed with the\nFood and Drug Administration under section 351(k) of\nthe Public Health Service Act (42 U.S.C. 262(k)) or has\nthe exclusive rights to distribute the biological\nproduct that is the subject of such application.\n(h) Effective Date.--This section applies with respect to\nagreements described in subsection (a) entered into on or after the\ndate of the enactment of this Act.\n\nSEC. 3. NOTICE AND CERTIFICATION OF AGREEMENTS.\n\n(a) Notice of All Agreements.--Section 1111(7) of the Medicare\nPrescription Drug, Improvement, and Modernization Act of 2003 (21\nU.S.C. 355 note) is amended by inserting ``or the owner of a patent for\nwhich a claim of infringement could reasonably be asserted against any\nperson for making, using, offering to sell, selling, or importing into\nthe United States a biological product that is the subject of a\nbiosimilar biological product application'' before the period at the\nend.\n(b) Certification of Agreements.--Section 1112 of such Act (21\nU.S.C. 355 note) is amended by adding at the end the following:\n``(d) Certification.--The Chief Executive Officer or the company\nofficial responsible for negotiating any agreement under subsection (a)\nor (b) that is required to be filed under subsection (c) shall, within\n30 days of such filing, execute and file with the Assistant Attorney\nGeneral and the Commission a certification as follows: `I declare that\nthe following is true, correct, and complete to the best of my\nknowledge: The materials filed with the Federal Trade Commission and\nthe Department of Justice under section 1112 of the Medicare\nPrescription Drug, Improvement, and Modernization Act of 2003, with\nrespect to the agreement referenced in this certification--\n```(1) represent the complete, final, and exclusive\nagreement between the parties;\n```(2) include any ancillary agreements that are contingent\nupon, provide a contingent condition for, were entered into\nwithin 30 days of, or are otherwise related to, the referenced\nagreement; and\n```(3) include written descriptions of any oral agreements,\nrepresentations, commitments, or promises between the parties\nthat are responsive to subsection (a) or (b) of such section\n1112 and have not been reduced to writing.'.''.\n\nSEC. 4. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD.\n\nSection 505(j)(5)(D)(i)(V) of the Federal Food, Drug, and Cosmetic\nAct (21 U.S.C. 355(j)(5)(D)(i)(V)) is amended by inserting ``section 2\nof the Protecting Consumer Access to Generic Drugs Act of 2026 or''\nafter ``that the agreement has violated''.\n\nSEC. 5. COMMISSION LITIGATION AUTHORITY.\n\nSection 16(a)(2) of the Federal Trade Commission Act (15 U.S.C.\n56(a)(2)) is amended--\n(1) in subparagraph (D), by striking ``or'' after the\nsemicolon;\n(2) in subparagraph (E), by inserting ``or'' after the\nsemicolon; and\n(3) by inserting after subparagraph (E) the following:\n``(F) under section 2(d)(3)(A) of the Protecting\nConsumer Access to Generic Drugs Act of 2026;''.\n\nSEC. 6. STATUTE OF LIMITATIONS.\n\n(a) In General.--Except as provided in subsection (b), the\nCommission shall commence any administrative proceeding or civil action\nto enforce section 2 of this Act not later than 6 years after the date\non which the parties to the agreement file the Notice of Agreement as\nprovided by section 1112(c)(2) and (d) of the Medicare Prescription\nDrug, Improvement, and Modernization Act of 2003 (21 U.S.C. 355 note).\n(b) Civil Action After Issuance of Cease and Desist Order.--If the\nCommission has issued a cease and desist order under section 5 of the\nFederal Trade Commission Act (15 U.S.C. 45) for violation of section 2\nof this Act and the proceeding for the issuance of such order was\ncommenced within the period required by subsection (a) of this section,\nsuch subsection does not prohibit the commencement, after such period,\nof a civil action under section 2(d)(3)(A) against a party to such\norder or a civil action under subsection (l) of such section 5 for\nviolation of such order.\n<all>","changes":[],"passport":{"data":{"act":{"jurisdiction":"США","title_official":"H.R. 10887 (IH) - Protecting Consumer Access to Generic Drugs Act of 2026","title_short":"","level":"законопроект","date_adopted":"2026-10-22 (внесение)","date_in_force":"","date_version":"","phased":"","status":"законопроект: на рассмотрении","sunset":"","regulator":"Федеральная торговая комиссия","related":""},"goal":{"problem":"защита конкуренции на рынке генерических препаратов и обеспечение доступа потребителей к доступным лекарствам","goal":"предотвращение недобросовестных практик производителей оригинальных препаратов, направленных на замедление выхода генериков на рынок","targets":"отсутствуют","scope":"производители оригинальных препаратов и производители генерических препаратов","exclusions":""},"subjects_note":{"protected":"потребители"},"subjects":[{"role":"производитель оригинального препарата; производитель генерического препарата","who":"держатель регистрационного удостоверения (NDA или BLA holder); последующий заявитель (субсиквенсер)","criteria":"наличие регистрационного удостоверения или исключительных прав на патент","count":""}],"norms":[{"address":"SEC. 5","addressee":"Федеральная торговая комиссия","essence":"расширение полномочий Комиссии по контролю за соблюдением законодательства о защите конкуренции на рынке генерических препаратов","type":"полномочие","mechanism":"контроль и надзор","cost_channel":"административные издержки","cost_kind":"постоянные","trigger":"отсутствие нарушений","sanction":"отсутствует","refs":"Федеральный торговый кодекс США","form":"административный порядок","in_force":"после вступления закона в силу","ru_analog":"отсутствует"}]},"made_by":"GigaChat-2","made_at":"2026-10-29 08:44:05","edited_at":null,"edited_by":null}}